Prof Simon Maxwell, Professor of Clinical Pharmacology and Prescribing, University of Edinburgh, said:
“The research is interesting but doesn’t prove anything at this point: the data are from a small and uncontrolled study. Remdesivir is currently being assessed in large scale clinical studies, which will be critical in determining whether it is a safe and effective treatment for COVID-19. This is not least because there were some adverse events (60%) reported in the current study, some of them serious (23%), including multiple organ failure, septic shock, acute kidney injury, and hypotension.”
|